Hartmanns Solution
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Hartmann’s Solution for Injection BP as Steriflex No. 11 or freeflex
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Steriflex No. 11 has the following composition:
|
Name |
Specification Reference |
%w/v |
|
Sodium Chloride for Injections |
EP |
0.6 |
|
Potassium Chloride BP |
EP |
0.04 |
|
Calcium Chloride BP Dihydrate |
EP |
0.027 |
|
Lactic Acid BP |
EP | |
|
Sodium Hydroxide BP | ||
|
Lactic Acid BP and Sodium Hydroxide BP are added in the form of 2M Sodium Lactate Solution or a Premade 50% Sodium Lactate Solution to produce a concentration of Sodium Lactate of |
0.317 |
3 PHARMACEUTICAL FORM
Intravenous infusion.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Steriflex No. 11 is indicated for the treatment of metabolic acidosis and dehydration with acidosis. It may be used to expand extracellular fluids or restore extracellular electrolyte in practically all patients. It may be used in the treatment of diabetic coma.
4.2 Posology and method of administration
Adults and Children
The volume and rate of infusion will depend upon the requirements of the individual patient and the judgement of the physician.
Elderly
Care should be taken to avoid circulatory overload, particularly in patients with cardiac and renal insufficiency.
For intravenous infusion.
4.3 Contraindications
Patients with sodium overload. This may occur with myocardial and renal damage, but also in the first five or six days after surgery or severe trauma when there may be an inability to excrete unwanted sodium. Steriflex No.11 should not be given to patients with cardiac arrhythmias. Lactate containing solutions are contraindicated in, patients with liver disease.
4.4 Special warnings and precautions for use
Although Steriflex No. 11 provides potassium, this is only enough to maintain the potassium content of extracellular fluid and would be quite inadequate for patients with severe potassium loss. Under these circumstances potassium supplements must be given. Lactate overdose in patients with heart disease may provoke arrhythmias and heart failure. ECG monitoring is recommended if Steriflex No. 11 is administered to such patients.
Use with caution in, patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary oedema and in toxaemia of pregnancy.
The label states: Do not use unless the solution is clear and free from particles.
4.5 Interaction with other medicinal products and other forms of interaction
No clinically significant interactions known.
4.6 Pregnancy and lactation
The safety of this product during pregnancy and lactation has not been assessed, but its use during these periods is not considered to constitute a hazard.
4.7 Effects on ability to drive and use machines
Not applicable.
4.8 Undesirable effects
Thrombosis of the vein is always a possibility with intravenous infusion.
4.9 Overdose
Overdosage may lead to fluid overload and electrolyte imbalance. The use of diuretic may be indicated for the treatment of fluid and electrolyte disturbance.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Potassium chloride, sodium chloride and calcium chloride provide essential ions to maintain the intracellular/extracellular milieu.
Sodium lactate is used as a source of bicarbonate ions, which will correct acid-base balance.
5.2 Pharmacokinetic properties
Sodium lactate is metabolised in the liver to sodium bicarbonate.
5.3 Preclinical safety data
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
|
Name |
Specification Reference |
%w/v |
|
Water for Injections in bulk BP |
EP |
To 100 |
|
Hydrochloric Acid BP |
EP |
QS |
|
Sodium Hydroxide BP |
BP |
QS |
6.2 Incompatibilities
Incompatible with amikacin, amphotericin B, benzylpenicillin, dobutamine, amiodarone, amsacrine, sodium nitroprusside, tetracyclines, sodium bicarbonate, sodium calcium edetate and sulphadiazine sodium.
Because of the nature of the plastic material of the Steriflex bag (PVC), this solution should not be used as a vehicle for the administration of drugs which may be sorbed to the surface of the bag to varying and significant degrees.
6.3 Shelf life
500 & 1000ml PVC Bags - 24 months.
500 & 1000ml Polyolefin Bags - 36 months.
6.4 Special precautions for storage
Store at 20 to 25°C.
6.5 Nature and contents of container
The container is a flexible 500 or 1000ml bag made of medical grade PVC.
The bag is sealed either in:
A hermetically sealed polythene bag or
A rectangular pouch consisting of polyamide/polythene composite or Polyamide/Polyethylene-Propylene composite laminate welded to polypropylene ethylene propylene composite plugged with a polycarbonate plug with either a bromobutyl - (West 448 1/45) or gum (West 7006/45) stopper
or
A flexible 500 or 1000ml polyolefme bag sealed in a polyolefine overwrap.
6.6 Special precautions for disposal
Opening the overwrap:
Locate the corner tabs at the end of the bag. Grip the two tabs and pull the two halves of the overwrap apart, releasing the bag onto a clean surface.
Setting up the solution:
Position the roller clamp of the giving-set to just below the drip chamber and close. Hold the base of the giving set port firmly and grip the wings of the twist of tab. Twist to remove the protective cover. Still holding the base of the giving-set port push the set spike fully into the port to ensure a leak proof connection. Prime the set in accordance with the manufacturer’s instructions.
7 MARKETING AUTHORISATION HOLDER
Fresenius Kabi Limited
Cestrian Court
Eastgateway
Manor Park
Runcorn
Chesire
WA7 1NT
8 MARKETING AUTHORISATION NUMBER
PL 08828/0083
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
28/07/1989 / 05/05/2005
10 DATE OF REVISION OF THE TEXT
18/01/2010